Hays Advisory’s Myriad Genetics MYGN Stock Holding History

Hays Advisory’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8	Closed	–	–	111
2018 Q1	$0	Buy	+8	New	+$271	﹤0.01%	151
2015 Q4	–	Sell	-218,834	Closed	-$8.2M	–	70
2015 Q3	$8.2M	Sell	218,834 -47,869	-18%	-$1.7M	1.24%	37
2015 Q2	$9.06M	Sell	266,703 -20,586	-7%	-$700K	1.31%	35
2015 Q1	$10.2M	Sell	287,289 -7,393	-3%	-$265K	1.31%	36
2014 Q4	$10M	Buy	+294,682	New	+$10.5M	1.34%	33

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hays Advisory's MYGN Position: Q2 2018 in Review

Hays Advisory sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 8 shares.

Hays Advisory first reported a position in MYGN in Q4 2014 and held it in 5 quarters. The position peaked at $10.2M in Q1 2015. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

Hays Advisory reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
Hays Advisory sold 8 Myriad Genetics shares in Q2 2018.
Hays Advisory first reported a position in Myriad Genetics in Q4 2014 and held it in 5 quarters.
Hays Advisory's Myriad Genetics position peaked at $10.2M in Q1 2015.
258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on Hays Advisory's 13F filing for Q2 2018, filed 23 Jul 2018.